Alembic Pharmaceuticals

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Difluprednate Ophthalmic Emulsion, 0.05%.

27 Jan, 2026 | 12:36pm • Source: BSE

Alembic Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 ,inter alia, to consider and...

20 Jan, 2026 | 10:28am • Source: BSE

Alembic Pharmaceuticals Limited announces USFDA Tentative approval for Bosutinib Tablets, 400 mg.

12 Jan, 2026 | 12:07pm • Source: BSE

Please find attached herewith the Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31st December, 2025

05 Jan, 2026 | 05:04pm • Source: BSE

Intimation of Closure of Trading Window.

26 Dec, 2025 | 12:20pm • Source: BSE

Alembic Pharmaceuticals Limited announces USFDA approval for Travoprost Ophthalmic Solutions

18 Dec, 2025 | 11:00am • Source: BSE

Please find attached Newspaper Publication of Special Window for re-lodgement of transfer of physical shares.

15 Dec, 2025 | 04:37pm • Source: BSE

Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Loteprednol...

11 Dec, 2025 | 12:13pm • Source: NSE

Alembic Pharmaceuticals Limited receives USFDA Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%

11 Dec, 2025 | 11:53am • Source: BSE

Please find attached herewith a copy of advertisement related to notice of loss of equity share certificate.

09 Dec, 2025 | 06:48pm • Source: BSE

Intimation of One on One Investor Meet

04 Dec, 2025 | 04:28pm • Source: BSE

Resignation of Senior Managerial Personnel

01 Dec, 2025 | 06:41pm • Source: BSE

Please find attached herewith the Transcript of Post Result Conference Call held on 04th November, 2025

11 Nov, 2025 | 12:07pm • Source: BSE

Please find attached herewith intimation regarding copy of newspaper advertisement related to notice of claiming shares from Company''s Unclaimed Suspense Account.

10 Nov, 2025 | 06:28pm • Source: BSE

Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 07, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Sumatriptan...

07 Nov, 2025 | 03:23pm • Source: NSE

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, Single-Dose Autoinjector System.

07 Nov, 2025 | 03:05pm • Source: BSE

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg and 140 mg.

07 Nov, 2025 | 12:35pm • Source: BSE

Please find attached herewith Intimation regarding Regulation 30

06 Nov, 2025 | 09:56pm • Source: BSE

Newspaper Publication of Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2025

05 Nov, 2025 | 02:34pm • Source: BSE

Submission of Audio Recording of Post Results Conference Call held on 4th November, 2025

04 Nov, 2025 | 06:01pm • Source: BSE